Radiance Therapeutics to present at LSI USA ’23 Emerging Medtech Summit

EMERYVILLE, Calif.–(BUSINESS WIRE)–Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller, MSc. MD, will be representing the company at the LSI USA ’23 Emerging Medtech Summit, which will take place on March 20-23, 2023 in Dana Point, California.

LSI USA ‘23 is a unique conference that brings together the most innovative emerging medtech players, accredited investors, and strategics looking for partnership and investment opportunities. Hosted by Life Science Intelligence (LSI), a premium market intelligence company focused on the medtech industry, the LSI USA ’23 Emerging Medtech Summit is a must-attend event for investors and innovators seeking opportunities for fruitful collaborations to forecast the future of medtech.

Dr. Laurence Marsteller will be sharing the latest developments from Radiance Therapeutics with the distinguished audience, focusing on introducing the business opportunity the company offers to those committed to improving ophthalmic healthcare.

Radiance Therapeutics is developing a device for the treatment of glaucoma patients with the goal of reducing filtration surgery postoperative complications.

CEO Laurence Marsteller said: “LSI USA ‘23 will be a great opportunity for us to explore potential partnerships and investment opportunities with some of the most creative and visionary minds in the industry. We look forward to sharing with them our recent advances and discussing the potential of beta therapy to improve ophthalmic treatment approaches. Events like this are essential for driving innovation in the medtech industry, and we are proud to be a part of it and to have the chance to collaborate with other like-minded individuals and companies to achieve more than we could alone.”

Dr. Marsteller will showcase the future development plans that RadianceTx® has for its brachytherapy source device, which received an FDA 510(k) clearance for use in episcleral brachytherapy of tumors and benign growths.


For additional information regarding Radiance Therapeutics and its technology, please contact:

Radiance Therapeutics CEO, Laurence Marsteller: [email protected]
Giorgio Pirazzini, GP Communications: [email protected]

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Generated by Feedzy

Are you in?

Subscribe to receive exclusive content and notifications to your inbox